Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity

2026/01/01 by Kimberly A. Gudzune, Caroline M. Apovian, Vanita R. Aroda +19 · 1 voice · 1 citation
Medicine · #Bariatric Surgery and Outcomes #Diabetes Treatment and Management #Pharmacology and Obesity Treatment

paper · pdf · doi:10.2337/doci25-0008

openalex publication_date 2026/01/01 · openalex created_date 2026/01/14 · openalex updated_date 2026/07/14

Abstract

Obesity medications may be part of a comprehensive care plan for adults with obesity. The Obesity Association, a division of the American Diabetes Association (ADA), developed comprehensive, evidence-based guidelines on the pharmacologic treatment of obesity in adults. When used in conjunction with lifestyle modifications, obesity medications have demonstrated efficacy in inducing and sustaining weight reduction while concurrently improving clinical outcomes of obesity and obesity-related diseases and complications. Health care professionals should engage people with obesity in a person-centered, shared decision-making approach when selecting an obesity medication to optimize health outcomes while emphasizing individual needs and preferences. The ADA’s Obesity Association encourages health care professionals to adopt these guidelines for treatment of obesity in adults.

Citations

• Weight-Loss Outcomes: A Systematic Review and Meta-Analysis of Weight-Loss Clinical Trials with a Minimum 1-Year Follow-Up
• The role of protein in weight loss and maintenance
• Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
• Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction
• Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
• Once-Weekly Semaglutide in Adults with Overweight or Obesity
• Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association
• Tirzepatide Once Weekly for the Treatment of Obesity
• Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
• Do Personalized Nutrition Interventions Improve Dietary Intake and Risk Factors in Adults With Elevated Cardiovascular Disease Risk Factors? A Systematic Review and Meta-analysis of Randomized Controlled Trials
• Definition and diagnostic criteria of clinical obesity
• Behavioral Treatment of Obesity in Patients Encountered in Primary Care Settings
• Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
• Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial
• Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

Cited by

• Benefits and Costs of Treating Obesity Among Adults in Commercial Insurance Plans

Discussions

• 📘 The first article from Diabetes, Obesity, and Cardiometabolic CARE is now published. This Standards of Care in Overweight and Obesity article provides evidence-based guidance on using obesity medi [bsky, 1 points, 0 comments]

Related

• Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults: Standards of Care in Overweight and Obesity—2026
• Lifestyle modification approaches for the treatment of obesity in adults.
• Obesity in adults: a clinical practice guideline
• Trends in Obesity Care Among US Adults, 2010–2021
• Obesity treatment in adolescents and adults in the era of personalized medicine